- Home
- SLI vs FLGT Comparison
SLI vs FLGT Comparison
Compare SLI & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLI
- FLGT
- Stock Information
- Founded
- SLI 1998
- FLGT 2011
- Country
- SLI Canada
- FLGT United States
- Employees
- SLI N/A
- FLGT N/A
- Industry
- SLI Major Chemicals
- FLGT Medical Specialities
- Sector
- SLI Industrials
- FLGT Health Care
- Exchange
- SLI Nasdaq
- FLGT Nasdaq
- Market Cap
- SLI 595.8M
- FLGT 587.3M
- IPO Year
- SLI N/A
- FLGT 2016
- Fundamental
- Price
- SLI $2.83
- FLGT $21.77
- Analyst Decision
- SLI Buy
- FLGT Buy
- Analyst Count
- SLI 2
- FLGT 3
- Target Price
- SLI $3.58
- FLGT $25.33
- AVG Volume (30 Days)
- SLI 1.8M
- FLGT 342.7K
- Earning Date
- SLI 08-08-2025
- FLGT 08-01-2025
- Dividend Yield
- SLI N/A
- FLGT N/A
- EPS Growth
- SLI N/A
- FLGT N/A
- EPS
- SLI N/A
- FLGT N/A
- Revenue
- SLI N/A
- FLGT $303,223,000.00
- Revenue This Year
- SLI N/A
- FLGT $11.79
- Revenue Next Year
- SLI N/A
- FLGT $10.45
- P/E Ratio
- SLI N/A
- FLGT N/A
- Revenue Growth
- SLI N/A
- FLGT 4.31
- 52 Week Low
- SLI $1.08
- FLGT $14.57
- 52 Week High
- SLI $3.09
- FLGT $23.99
- Technical
- Relative Strength Index (RSI)
- SLI 58.76
- FLGT 66.01
- Support Level
- SLI $2.66
- FLGT $21.09
- Resistance Level
- SLI $3.09
- FLGT $21.74
- Average True Range (ATR)
- SLI 0.18
- FLGT 0.76
- MACD
- SLI -0.01
- FLGT 0.14
- Stochastic Oscillator
- SLI 59.84
- FLGT 89.04
About SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.